IL1B and rheumatoid arthritis: Interestingly, the downstream TNF, IL-1, and IL-6 signatures tended to be more enriched in LA than RA, indicating potential for repurposing anti-TNF biologics, the IL-1 antagonists anakinra and canakinumab, and IL-6R antagonist tocilizumab to treat LA.